A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Inclusion Criteria

• •Male or female participants ≥ 18 years of age at the time of signing the informed consent
• •Have an ECOG performance status score of 0 to 2
• •Have an established cytopathologically confirmed diagnosis of BCR-ABL1 positive CML in Chronic Phase
• •Have received treatment with at least one prior TKI and have treatment failure, suboptimal response, or treatment intolerance
• •Prior treatment with asciminib is allowed
• •Adequate organ function, as assessed by local laboratory